Plain-English translation of NCT06901245 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a medication given as a once-weekly injection, to see if it can help young adults (ages 18–26) manage obesity. The study includes three groups: people with Prader-Willi Syndrome, people with hypothalamic obesity (obesity caused by damage to a part of the brain that controls hunger), and people with obesity unrelated to any genetic or medical condition. Researchers want to learn whether this medication is safe and effective for these young adults.
Obesity in young adults—especially when it's linked to genetic conditions or brain-related causes—is difficult to treat with diet and exercise alone. This trial exists to find out whether this medication could offer a new treatment option for these young people who have limited options today.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll receive the medication as a once-weekly injection for about 56–60 weeks (roughly a year). You'll attend 6 in-person visits at the study site and 4 visits by video call. At these visits, the research team will check your vital signs, measure your weight and waist, take blood and urine samples, do a special scan to measure your body composition, and ask you questions about how you're doing. Your involvement will help researchers understand whether this treatment can safely help young adults with these types of obesity.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States